



Resolution n° 6-2018-e

Go-ahead for the development of a grant agreement package for the extension and expansion of the Expand New Drug Markets for TB Project

Recalling Unitaid Executive Board Resolution EB19/SSP/2014/R1 of 5 May 2014, in which the Board approved the commitment of up to US\$ 60,369,772 for the project entitled “Expand New Drug Markets for TB (endTB)” (the “Project”), to be implemented by Partners in Health for a four-year period; and

Taking into account the assessment by the Joint Review Committee of the proposed project by Partners in Health entitled “endTB-Q: A clinical trial for innovative treatment regimens for fluoroquinolone-resistant MDR-TB”, under the area of intervention “Better shorter treatment for MDR TB” (the “endTB-Q Proposal”);

The Executive Board authorizes the Secretariat to go-ahead with the development of a draft grant agreement package for subsequent submission to the Board for approval, that:

- a) Extends the duration of the ongoing endTB Project until a date no later than December 2022 (exact date to be defined during grant agreement development), in order to allow for completion of the current clinical trial; and
- b) Expands the scope of the Project to include a new clinical trial targeting FQ-resistant MDR-TB patients, as envisaged in the endTB-Q Proposal.

The budget for the expansion of the Project shall reflect minimal incremental costs, the exploration of opportunities for co-funding and cost-efficiencies to be identified in the development of the grant extension budget. The budget will be submitted to the Board for approval with the grant package.

This go-ahead decision has no budgetary implications.

Sarah Boulton
Vice-Chair of the Unitaid Executive Board
Date: 25/06/2018